These data provide an explanation for the lack of positive clinical trial data from using HER inhibitors in the endocrine-therapy-resistant ER+/HER2− breast cancer setting, in spite of strong preclinical links between ER loss and upregulation of HER23,4. Here, ESR1 is linked to breast cancer.